ATE374029T1 - Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo - Google Patents

Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo

Info

Publication number
ATE374029T1
ATE374029T1 AT99937631T AT99937631T ATE374029T1 AT E374029 T1 ATE374029 T1 AT E374029T1 AT 99937631 T AT99937631 T AT 99937631T AT 99937631 T AT99937631 T AT 99937631T AT E374029 T1 ATE374029 T1 AT E374029T1
Authority
AT
Austria
Prior art keywords
vivo
disease
increase
treating alzheimer
cytidine levels
Prior art date
Application number
AT99937631T
Other languages
English (en)
Inventor
Carol Watkins
Richard Wurtman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE374029T1 publication Critical patent/ATE374029T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99937631T 1998-07-31 1999-07-30 Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo ATE374029T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9500298P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
ATE374029T1 true ATE374029T1 (de) 2007-10-15

Family

ID=22248474

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99937631T ATE374029T1 (de) 1998-07-31 1999-07-30 Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
AT07116909T ATE446097T1 (de) 1998-07-31 1999-07-30 Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07116909T ATE446097T1 (de) 1998-07-31 1999-07-30 Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen

Country Status (11)

Country Link
US (1) US6989376B2 (de)
EP (5) EP2145627B1 (de)
JP (1) JP2003517437A (de)
AT (2) ATE374029T1 (de)
CA (1) CA2339008C (de)
CY (1) CY1110570T1 (de)
DE (2) DE69941586D1 (de)
DK (5) DK1140104T3 (de)
ES (5) ES2294850T3 (de)
PT (5) PT1140104E (de)
WO (1) WO2000006174A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) * 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
EA008179B1 (ru) * 2002-07-11 2007-04-27 Ямаса Корпорейшн Цитидин-5'-дифосфохолин для профилактики или лечения токсической (лекарственно-индуцированной) периферической невропатии
MXPA05004866A (es) * 2002-11-08 2005-11-04 Mclean Hospital Corp Compuestos para el tratamiento de la dependencia y la abstinencia de tabaco.
RU2366428C2 (ru) * 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Соединения для нормализации цикла сна/бодрствования
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2566612C (en) 2004-05-13 2015-06-30 Massachusetts Institute Of Technology Uridine effects on dopamine release
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006031683A2 (en) * 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
AU2011253660B2 (en) * 2004-09-15 2013-12-19 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
AU2012203650B2 (en) * 2005-05-23 2014-09-18 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
ES2624702T5 (es) * 2005-05-23 2020-12-11 Massachusetts Inst Technology Composiciones que contienen PUFA y/o uridina y métodos para su uso
NZ566842A (en) * 2005-09-22 2011-12-22 Megmilk Snow Brand Co Ltd Use of sphingomyelin for preventing or reducing alcohol intoxication and/or hangover
EP1951308B1 (de) * 2005-11-25 2013-02-20 Gisela Susilo Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
JP5140584B2 (ja) * 2006-06-27 2013-02-06 ヤマサ醤油株式会社 抗心理社会的ストレス剤
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
US8551452B2 (en) * 2007-11-02 2013-10-08 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
CA2727546A1 (en) * 2008-06-12 2009-12-17 Repligen Corporation Methods of treatment of bipolar disorder
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CN107353316B (zh) 2011-09-30 2020-08-18 塔夫斯大学 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2014027882A1 (en) 2012-08-13 2014-02-20 N.V. Nutricia Product and method for supporting uridine homeostasis
WO2014052896A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
HUE039871T2 (hu) 2013-03-13 2019-02-28 Univ Tufts Uridin nukleozid származékok, kompozíciók és alkalmazási eljárások
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
WO2015115885A1 (en) * 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
WO2016053085A1 (en) * 2014-09-30 2016-04-07 N.V. Nutricia Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders
WO2016072842A1 (en) * 2014-11-05 2016-05-12 N.V. Nutricia Method for preventing, reducing the risk of, or treating behavioral frontotemporal dementia
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
ES2947592T3 (es) 2016-04-04 2023-08-11 Nutricia Nv Composición para su uso en la reducción o prevención del retraso global del desarrollo de los niños
KR20250084233A (ko) * 2018-02-01 2025-06-10 파마 싱크, 엘엘씨 우리딘의 전신 전달을 위한 조성물 및 장치
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
CN114990176A (zh) * 2022-05-26 2022-09-02 宁夏华吉生物有限公司 一种生产尿嘧啶核苷的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508474A1 (de) * 1975-02-27 1976-09-02 Boehringer Mannheim Gmbh Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen
DE2629845A1 (de) * 1976-07-02 1978-01-05 Geb Graze Erika Graze Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
US4609647A (en) * 1985-05-28 1986-09-02 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition and process
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
EP0339075B1 (de) * 1987-10-28 1993-08-18 Pro-Neuron, Inc. Acylatiertes uridin und cytidin und deren verwendungen
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2003332C1 (ru) 1989-06-09 1993-11-30 Борис Витальевич Страдомский Средство дл лечени депрессий
JPH0722495B2 (ja) * 1990-01-30 1995-03-15 美穂 田中 クロレラ含有油脂食品
US5141943A (en) 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
JPH07215879A (ja) * 1994-02-02 1995-08-15 Otsuka Pharmaceut Factory Inc 抗ストレス組成物
DE9412374U1 (de) * 1994-08-01 1994-09-22 Rauch-Petz, Gisela G., Dr., 80803 München Nahrungsergänzungsmittel
JPH0930976A (ja) * 1995-07-17 1997-02-04 Otsuka Pharmaceut Factory Inc 記憶低下改善剤
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
RU2394580C2 (ru) * 1999-02-23 2010-07-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы лечения митохондриальных нарушений
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
EP1870103A3 (de) 2008-08-06
EP1870103B1 (de) 2009-10-21
EP1870103A2 (de) 2007-12-26
ES2477568T3 (es) 2014-07-17
EP1140104A1 (de) 2001-10-10
DK2329829T3 (da) 2014-07-21
CA2339008A1 (en) 2000-02-10
PT2145627E (pt) 2014-07-24
EP2329829B1 (de) 2014-04-16
WO2000006174A1 (en) 2000-02-10
DK1140104T3 (da) 2008-01-21
DK1870103T3 (da) 2010-01-11
DK2322187T3 (da) 2014-07-21
EP2329829A2 (de) 2011-06-08
DK2145627T3 (da) 2014-07-21
EP2145627B1 (de) 2014-04-16
DE69941586D1 (de) 2009-12-03
PT2329829E (pt) 2014-07-24
CY1110570T1 (el) 2015-04-29
PT1870103E (pt) 2010-02-23
EP2329829A3 (de) 2011-07-20
US20020028787A1 (en) 2002-03-07
PT1140104E (pt) 2007-12-26
ES2294850T3 (es) 2008-04-01
EP1140104B1 (de) 2007-09-26
EP1140104A4 (de) 2004-12-22
ES2478044T3 (es) 2014-07-18
PT2322187E (pt) 2014-07-24
EP2322187B1 (de) 2014-05-14
EP2322187A3 (de) 2011-07-20
US6989376B2 (en) 2006-01-24
DE69937198T2 (de) 2008-07-03
EP2322187A2 (de) 2011-05-18
ES2476940T3 (es) 2014-07-15
JP2003517437A (ja) 2003-05-27
DE69937198D1 (de) 2007-11-08
ES2332669T3 (es) 2010-02-10
ATE446097T1 (de) 2009-11-15
CA2339008C (en) 2009-12-15
EP2145627A1 (de) 2010-01-20

Similar Documents

Publication Publication Date Title
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
GB0108592D0 (en) Therapeutic agents
AU2001257451A8 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
IL159300A0 (en) Prodrugs of gaba analogs, compositions and uses thereof
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69836783D1 (de) Methode zur Behandlung des Tourette-Syndroms
ZA991641B (en) Treatment of viral disease in swine.
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
EP1392855A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung einer viruserkrankung unter verwendung von 55092
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
BG102864A (en) Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions
HUP9903165A3 (en) Use of amosulalol for the preparation of pharmaceutical compositions treating ocular circulation disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140104

Country of ref document: EP